SANGUINE CORP. (SGNC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: R>G> who wrote (2536)	7/5/1998 1:26:00 AM
From: chirodoc	Read Replies (2) of 5402

israeli center for technological research has this to say........... TITLE: Perfluorcarbon Formulation that Enhances Wound Healing Processes SUMMARY: A perfluorcarbon emulsion is developed for enhancing wound healing. Sufficient oxygen is supplied to the damaged tissue. Animal tests have demonstrated efficacy. University research project. ABSTRACT: A newly developed proprietary formulation has been shown to enhance the process of wound healing. It is a perfluorocarbon emulsion that contains materials of biological origin. The ability of various perfluorocarbon compounds to dissolve and release oxygen has been recognized as potentially very beneficial, spurring their use in the development of various systematically administered blood substitutes. The same properties are to be utilized in order to supply oxygen to a damaged tissue, to support its healing process. Initial animal experiments have demonstrated the efficacy of the new formulation, with perfluorocarbons supplying the needed oxygen and the added biological substances cell functions. Additional work now under way, including further animal tests and clinical trials, aims at the ultimate commercialization of this development. University research project.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next